[{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"09e74a0b-2911-4165-9b8f-e77d19ed6b2f","acronym":"TroFuse-004","url":"https://clinicaltrials.gov/study/NCT06074588","created_at":"2023-10-10T14:11:53.919Z","updated_at":"2025-02-25T13:49:58.239Z","phase":"Phase 3","brief_title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","source_id_and_acronym":"NCT06074588 - TroFuse-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 556","initiation":"Initiation: 11/12/2023","start_date":" 11/12/2023","primary_txt":" Primary completion: 05/10/2027","primary_completion_date":" 05/10/2027","study_txt":" Completion: 03/11/2030","study_completion_date":" 03/11/2030","last_update_posted":"2025-02-20"},{"id":"6443d84d-18f2-435e-a44c-d58932c7c829","acronym":"SKB264-II-04","url":"https://clinicaltrials.gov/study/NCT05816252","created_at":"2023-04-18T15:04:37.057Z","updated_at":"2025-02-25T15:20:25.216Z","phase":"Phase 2","brief_title":"A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05816252 - SKB264-II-04","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tagrisso (osimertinib) • carboplatin • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-02-12"},{"id":"de32242c-e2ef-4e4e-af03-36f807029c84","acronym":"KL264-01","url":"https://clinicaltrials.gov/study/NCT04152499","created_at":"2021-01-18T20:16:04.885Z","updated_at":"2025-02-25T16:25:32.908Z","phase":"Phase 1/2","brief_title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","source_id_and_acronym":"NCT04152499 - KL264-01","lead_sponsor":"Klus Pharma Inc.","biomarkers":" EGFR • HER-2 • MSI • BRCA • TACSTD2","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation","tags":["EGFR • HER-2 • MSI • BRCA • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative • HER-2 expression • EGFR wild-type • HER-2 underexpression • TROP2 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/16/2026","study_completion_date":" 07/16/2026","last_update_posted":"2024-06-24"},{"id":"267ec5cc-b724-4169-9143-1dd0cacff9e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06049212","created_at":"2023-09-22T14:10:32.880Z","updated_at":"2024-07-02T16:35:04.537Z","phase":"Phase 1","brief_title":"Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)","source_id_and_acronym":"NCT06049212","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 06/06/2025","primary_completion_date":" 06/06/2025","study_txt":" Completion: 06/06/2025","study_completion_date":" 06/06/2025","last_update_posted":"2024-05-10"},{"id":"40c12235-7a66-4e0e-89ba-dbffecad221c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05351788","created_at":"2022-04-28T16:57:05.872Z","updated_at":"2024-07-02T16:35:26.230Z","phase":"Phase 2","brief_title":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05351788","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • ALK fusion • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • ALK fusion • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-12-14"},{"id":"5f1b88b0-cdc5-4d74-a80d-bc246071b07a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631262","created_at":"2023-10-24T17:13:56.241Z","updated_at":"2024-07-02T16:35:32.045Z","phase":"Phase 2","brief_title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05631262","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2023-10-24"},{"id":"4aa2437c-ec63-45ac-b45d-743638a6c18c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445908","created_at":"2023-10-24T00:13:52.884Z","updated_at":"2024-07-02T16:35:32.398Z","phase":"Phase 2","brief_title":"SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer","source_id_and_acronym":"NCT05445908","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jiataile (sacituzumab tirumotecan) • Cotelet (tagitanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-20"},{"id":"a544e8bf-0923-4309-b003-451edd56ff00","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347134","created_at":"2022-04-26T13:53:52.328Z","updated_at":"2024-07-02T16:35:32.427Z","phase":"Phase 3","brief_title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","source_id_and_acronym":"NCT05347134","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative","tags":["HER-2 • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-20"},{"id":"3459c1c8-102f-49bc-b1d1-56f9bcdcff46","acronym":"SKB264-Ⅲ-10","url":"https://clinicaltrials.gov/study/NCT06081959","created_at":"2023-10-14T01:13:11.046Z","updated_at":"2024-07-02T16:35:33.641Z","phase":"Phase 3","brief_title":"A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06081959 - SKB264-Ⅲ-10","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 376","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-10-13"}]